{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:53:23Z","timestamp":1740142403993,"version":"3.37.3"},"reference-count":82,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007052","name":"Memorial Sloan Kettering Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.hoc.2024.01.005","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T14:59:12Z","timestamp":1709132352000},"page":"643-657","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunotherapy"],"prefix":"10.1016","volume":"38","author":[{"given":"Layal","family":"Al Mahmasani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James J.","family":"Harding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghassan","family":"Abou-Alfa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.hoc.2024.01.005_bib1","first-page":"325","article-title":"Distal cholangiocarcinoma","volume":"94","author":"Dickson","year":"2014","journal-title":"Surgical Clinics"},{"issue":"2","key":"10.1016\/j.hoc.2024.01.005_bib2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.gtc.2018.01.002","article-title":"Liver Transplant for Cholangiocarcinoma","volume":"47","author":"Zamora-Valdes","year":"2018","journal-title":"Gastroenterol Clin North Am"},{"issue":"5","key":"10.1016\/j.hoc.2024.01.005_bib3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.21037\/cco.2016.10.03","article-title":"Surgical management of biliary tract cancers","volume":"5","author":"Fairweather","year":"2016","journal-title":"Chin Clin Oncol"},{"issue":"25","key":"10.1016\/j.hoc.2024.01.005_bib4","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in Advanced Solid Tumors Harboring a KRAS(G12C) Mutation","volume":"41","author":"Bekaii-Saab","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"10.1016\/j.hoc.2024.01.005_bib5","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.hoc.2024.01.005_bib6","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM evidence"},{"issue":"10391","key":"10.1016\/j.hoc.2024.01.005_bib7","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.hoc.2024.01.005_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/cells12162098","article-title":"Lacking Immunotherapy Biomarkers for Biliary Tract Cancer: A Comprehensive Systematic Literature Review and Meta-Analysis","volume":"12","author":"Frega","year":"2023","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.hoc.2024.01.005_bib9","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.dld.2018.11.018","article-title":"Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer (AMEBICA)-PRODIGE 38: Study protocol for a randomized controlled multicenter phase II\/III study","volume":"51","author":"Phelip","year":"2019","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.hoc.2024.01.005_bib10","doi-asserted-by":"crossref","unstructured":"Shroff RT, Guthrie KA, Scott AJ, et al. SWOG 1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers, J Clin Oncol, 41, 2023 (suppl 4, abstr LBA490).","DOI":"10.1200\/JCO.2023.41.4_suppl.LBA490"},{"issue":"1","key":"10.1016\/j.hoc.2024.01.005_bib11","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/jhbp.1219","article-title":"Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA)","volume":"30","author":"Ioka","year":"2023","journal-title":"J\u00a0Hepatobiliary Pancreat Sci"},{"key":"10.1016\/j.hoc.2024.01.005_bib12","unstructured":"NCCN guidelines on management of Biliary tract cancers. V. 3 2023."},{"issue":"5","key":"10.1016\/j.hoc.2024.01.005_bib13","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/cncr.34020","article-title":"Equipoise, drug development, and biliary cancer","volume":"128","author":"Lee","year":"2022","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.hoc.2024.01.005_bib14","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2024.01.005_bib15","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ejca.2021.06.019","article-title":"A\u00a0randomised phase II study of oxaliplatin\/5-FU (mFOLFOX) versus irinotecan\/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine\/cisplatin chemotherapy","volume":"154","author":"Choi","year":"2021","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.hoc.2024.01.005_bib16","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/S1470-2045(21)00486-1","article-title":"Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study","volume":"22","author":"Yoo","year":"2021","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.hoc.2024.01.005_bib17","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1002\/cncr.32463","article-title":"Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes","volume":"125","author":"Lowery","year":"2019","journal-title":"Cancer"},{"issue":"24","key":"10.1016\/j.hoc.2024.01.005_bib18","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1002\/cncr.30254","article-title":"Biliary cancer: utility of next-generation sequencing for clinical management","volume":"122","author":"Javle","year":"2016","journal-title":"Cancer"},{"issue":"17","key":"10.1016\/j.hoc.2024.01.005_bib19","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","article-title":"Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention","volume":"24","author":"Lowery","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2024.01.005_bib20","doi-asserted-by":"crossref","first-page":"e2100510","DOI":"10.1200\/PO.21.00510","article-title":"Clinical, genomic, and transcriptomic data profiling of biliary tract cancer reveals subtype-specific immune signatures","volume":"6","author":"Mody","year":"2022","journal-title":"JCO Precision Oncology"},{"key":"10.1016\/j.hoc.2024.01.005_bib21","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1200\/EDBK_160831","article-title":"Biliary tract cancer: epidemiology, radiotherapy, and molecular profiling","volume":"36","author":"Bridgewater","year":"2016","journal-title":"American Society of Clinical Oncology Educational Book"},{"issue":"1","key":"10.1016\/j.hoc.2024.01.005_bib22","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2022.09.004","article-title":"Rational development of combination therapies for biliary tract cancers","volume":"78","author":"Harding","year":"2023","journal-title":"J\u00a0Hepatol"},{"issue":"9","key":"10.1016\/j.hoc.2024.01.005_bib23","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S2468-1253(19)30189-X","article-title":"Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study","volume":"4","author":"Lowery","year":"2019","journal-title":"Lancet Gastroenterology & Hepatology"},{"issue":"6","key":"10.1016\/j.hoc.2024.01.005_bib24","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2024.01.005_bib25","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical claridhy trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2024.01.005_bib26","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1158\/2159-8290.CD-18-0877","article-title":"Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition","volume":"8","author":"Harding","year":"2018","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.hoc.2024.01.005_bib27","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41698-022-00304-5","article-title":"Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma","volume":"6","author":"Cleary","year":"2022","journal-title":"npj Precis Oncol"},{"issue":"8_Supplement","key":"10.1016\/j.hoc.2024.01.005_bib28","doi-asserted-by":"crossref","first-page":"CT098","DOI":"10.1158\/1538-7445.AM2023-CT098","article-title":"Abstract CT098: A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH, in advanced IDH-mutant cholangiocarcinoma and other solid tumors","volume":"83","author":"Rodon","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2024.01.005_bib29","unstructured":"Clinicaltrials.gov. 2023. clinicaltrial.gov\/study\/NCT04056910."},{"issue":"13","key":"10.1016\/j.hoc.2024.01.005_bib30","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.3390\/cancers15133312","article-title":"Immunotherapy in Biliary Tract Cancers: Current Standard-of-Care and Emerging Strategies","volume":"15","author":"Lo","year":"2023","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.hoc.2024.01.005_bib31","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","article-title":"Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma","volume":"36","author":"Javle","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"30","key":"10.1016\/j.hoc.2024.01.005_bib32","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.2217\/fon-2020-0299","article-title":"Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions\/translocations: the PROOF 301 trial","volume":"16","author":"Makawita","year":"2020","journal-title":"Future Oncol"},{"key":"10.1016\/j.hoc.2024.01.005_bib33","unstructured":"https:\/\/www.biospace.com\/article\/bridgebio-takes-hit-as-partner-ends-2-4b-partnership-for-liver-cancer-candidate\/. 2023."},{"key":"10.1016\/j.hoc.2024.01.005_bib34","doi-asserted-by":"crossref","unstructured":"Abou-Alfa GK, Borbath I, Goyal L, et al. Proof 301: a multicenter, open-label, randomized, phase 3 trial of infigratinib versus gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma with an FGFR2 gene fusion\/rearrangement, 2022, J Clini Oncol, 40, 16 (TSP4171).","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS4171"},{"issue":"5","key":"10.1016\/j.hoc.2024.01.005_bib35","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2024.01.005_bib36","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2024.01.005_bib37","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1200\/JCO.2023.41.16_suppl.3074","article-title":"Genomic characterization of FGFR-altered solid tumors using a clinically annotated pan-cancer repository","volume":"41","author":"Choudhury","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2024.01.005_bib38","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-19-2035","article-title":"Facts and new hopes on selective FGFR inhibitors in solid tumors","volume":"26","author":"Facchinetti","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1016\/j.hoc.2024.01.005_bib39","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.3390\/cancers15184446","article-title":"Targetable Molecular Alterations in the Treatment of Biliary Tract Cancers: An Overview of the Available Treatments","volume":"15","author":"Valery","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.hoc.2024.01.005_bib40","doi-asserted-by":"crossref","first-page":"S1381","DOI":"10.1016\/j.annonc.2022.08.006","article-title":"LBA12 Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f\/r), FGFR inhibitor (FGFRi)-na\u00efve cholangiocarcinoma (CCA): ReFocus trial","volume":"33","author":"Hollebecque","year":"2022","journal-title":"Ann Oncol"},{"year":"2023","series-title":"Gunagratinib, a highly selective irreversible FGFR inhibitor, in patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring FGFR pathway alterations: a phase IIa dose-expansion study","author":"Guo","key":"10.1016\/j.hoc.2024.01.005_bib41"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2024.01.005_bib42","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.2019.37.15_suppl.3002","article-title":"Dabrafenib and trametinib in patients with tumors with BRAF V600E\/K mutations: Results from the molecular analysis for therapy choice (MATCH) Arm H","volume":"37","author":"Salama","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2024.01.005_bib43","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1158\/2159-8290.CD-18-1321","article-title":"Targeting Alterations in the RAF-MEK Pathway","volume":"9","author":"Yaeger","year":"2019","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.hoc.2024.01.005_bib44","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/jclinpath-2015-203394","article-title":"Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets","volume":"69","author":"Hwajeong","year":"2016","journal-title":"J\u00a0Clin Pathol"},{"issue":"9","key":"10.1016\/j.hoc.2024.01.005_bib45","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.hoc.2024.01.005_bib46","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.2217\/fon-2022-0214","article-title":"Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial","volume":"18","author":"Ohba","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.hoc.2024.01.005_bib47","doi-asserted-by":"crossref","unstructured":"Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results, 2023, J Clin Oncol, 41, 17 (LBA3000).","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA3000"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2024.01.005_bib48","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1200\/JCO.2023.41.16_suppl.4008","article-title":"Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2-amplified biliary tract cancer (BTC)","volume":"41","author":"Pant","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2024.01.005_bib49","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2024.01.005_bib50","doi-asserted-by":"crossref","first-page":"S273","DOI":"10.1016\/j.annonc.2022.04.164","article-title":"P-74 SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations: Biliary tract cancer cohort (trial in progress)","volume":"33","author":"Bekaii-Saab","year":"2022","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2024.01.005_bib51","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1200\/JCO.2023.41.16_suppl.4007","article-title":"Tucatinib and trastuzumab for previously treated HER2-positive metastatic biliary tract cancer (SGNTUC-019): A phase 2 basket study","volume":"41","author":"Nakamura","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2024.01.005_bib52","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41467-023-36399-y","article-title":"Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers","volume":"14","author":"Harding","year":"2023","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.hoc.2024.01.005_bib53","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2024.01.005_bib54","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/s41591-022-01931-y","article-title":"Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1\/2 ARROW trial","volume":"28","author":"Subbiah","year":"2022","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.hoc.2024.01.005_bib55","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2024.01.005_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14071748","article-title":"Evolving Role of Immunotherapy in Advanced Biliary Tract Cancers","volume":"14","author":"Kang","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.hoc.2024.01.005_bib57","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/1568009053332627","article-title":"MDM2 is a central node in the p53 pathway: 12 years and counting","volume":"5","author":"Bond","year":"2005","journal-title":"Curr Cancer Drug Targets"},{"issue":"7","key":"10.1016\/j.hoc.2024.01.005_bib58","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1007\/s00044-023-03102-1","article-title":"Targeting MDM2 for the development of a new cancer therapy: progress and challenges","volume":"32","author":"Aguilar","year":"2023","journal-title":"Med Chem Res"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2024.01.005_bib59","doi-asserted-by":"crossref","first-page":"TPS4179","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS4179","article-title":"A\u00a0phase IIa\/IIb, open-label trial of BI 907828, an MDM2\u2013p53 antagonist, in patients with locally advanced\/metastatic biliary tract carcinoma or pancreatic ductal adenocarcinoma: Brightline-2","volume":"41","author":"Goyal","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2024.01.005_bib60","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1158\/2159-8290.CD-23-0153","article-title":"The MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study","volume":"13","author":"LoRusso","year":"2023","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.hoc.2024.01.005_bib61","doi-asserted-by":"crossref","first-page":"2124666","DOI":"10.1080\/2162402X.2022.2124666","article-title":"Immune targeting of three independent suppressive pathways (TIGIT, PD-L1, TGF\u03b2) provides significant antitumor efficacy in immune checkpoint resistant models","volume":"11","author":"Franks","year":"2022","journal-title":"OncoImmunology"},{"year":"2021","series-title":"Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase II LEAP-005 study","author":"Villanueva","key":"10.1016\/j.hoc.2024.01.005_bib62"},{"key":"10.1016\/j.hoc.2024.01.005_bib63","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211036544","article-title":"IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer","volume":"13","author":"Hack","year":"2021","journal-title":"Therapeutic Advances in Medical Oncology"},{"issue":"2","key":"10.1016\/j.hoc.2024.01.005_bib64","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1634\/theoncologist.2019-0233","article-title":"The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma","volume":"25","author":"Ali","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.hoc.2024.01.005_bib65","doi-asserted-by":"crossref","first-page":"1025608","DOI":"10.3389\/fimmu.2022.1025608","article-title":"Advances in CAR T-cell therapy in bile duct, pancreatic, and gastric cancers","volume":"13","author":"Feng","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.hoc.2024.01.005_bib66","doi-asserted-by":"crossref","first-page":"107069","DOI":"10.1016\/j.intimp.2020.107069","article-title":"Anti-tumour effect of the fourth-generation chimeric antigen receptor T\u00a0cells targeting CD133 against cholangiocarcinoma cells","volume":"89","author":"Sangsuwannukul","year":"2020","journal-title":"Int Immunopharm"},{"issue":"2","key":"10.1016\/j.hoc.2024.01.005_bib67","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","article-title":"Mesothelin-specific chimeric antigen receptor mRNA-engineered T\u00a0cells induce anti-tumor activity in solid malignancies","volume":"2","author":"Beatty","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"11","key":"10.1016\/j.hoc.2024.01.005_bib68","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113404","article-title":"A\u00a0Perspective on Cell Therapy and Cancer Vaccine in Biliary Tract Cancers (BTCs)","volume":"12","author":"Han","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.hoc.2024.01.005_bib69","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1007\/s00262-018-2157-5","article-title":"Tumor lysate-based vaccines: on the road to immunotherapy for gallbladder cancer","volume":"67","author":"Rojas-Sep\u00falveda","year":"2018","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"10.1016\/j.hoc.2024.01.005_bib70","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jama.2012.7352","article-title":"Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial","volume":"308","author":"Neoptolemos","year":"2012","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.hoc.2024.01.005_bib71","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.18.00050","article-title":"Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study","volume":"37","author":"Edeline","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2024.01.005_bib72","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/bjs.10776","article-title":"Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer","volume":"105","author":"Ebata","year":"2018","journal-title":"Journal of British Surgery"},{"issue":"24","key":"10.1016\/j.hoc.2024.01.005_bib73","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1200\/JCO.2014.60.2219","article-title":"SWOG S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma","volume":"33","author":"Ben-Josef","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2024.01.005_bib74","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10372","key":"10.1016\/j.hoc.2024.01.005_bib75","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0140-6736(22)02038-4","article-title":"Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"401","author":"Nakachi","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2024.01.005_bib76","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231163785","article-title":"Adjuvant therapy of biliary tract cancers","volume":"15","author":"Kefas","year":"2023","journal-title":"Ther Adv Med Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2024.01.005_bib77","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1245\/s10434-022-12863-9","article-title":"Adjuvant chemoradiation in patients with lymph node-positive biliary tract cancers: secondary analysis of a single-arm clinical trial (Swog 0809)","volume":"30","author":"Gholami","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2024.01.005_bib78","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1245\/s10434-022-12865-7","article-title":"Comparing Apples to Oranges: Commentary on a Secondary Analysis of SWOG 0809","volume":"30","author":"Warner","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2024.01.005_bib79","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13071647","article-title":"Current Status and Future Perspectives of Perioperative Therapy for Resectable Biliary Tract Cancer: A Multidisciplinary Review","volume":"13","author":"Yoo","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.hoc.2024.01.005_bib80","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3322\/caac.21759","article-title":"Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians","volume":"73","author":"Moris","year":"2023","journal-title":"CA A Cancer J Clin"},{"issue":"4_suppl","key":"10.1016\/j.hoc.2024.01.005_bib81","doi-asserted-by":"crossref","first-page":"TPS620","DOI":"10.1200\/JCO.2023.41.4_suppl.TPS620","article-title":"Optimal perioperative therapy for incidental gallbladder cancer (OPT-IN): A randomized phase II\/III trial\u2014ECOG-ACRIN EA2197","volume":"41","author":"Maithel","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2024.01.005_bib82","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.2022.40.16_suppl.4097","article-title":"NEO-GAP: A phase II single-arm prospective feasibility study of neoadjuvant gemcitabine\/cisplatin\/nab-paclitaxel for resectable high-risk intrahepatic cholangiocarcinoma","volume":"40","author":"Maithel","year":"2022","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858824000054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858824000054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T23:08:50Z","timestamp":1714691330000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858824000054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":82,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S0889858824000054"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2024.01.005","relation":{},"ISSN":["0889-8588"],"issn-type":[{"type":"print","value":"0889-8588"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2024.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}